Aspira Pathlab Fair Value
Aspira Pathlab (ASPIRA) average fair value is ₹16.63 across 5 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, vs a current market price of ₹115.0 (-85.54%), fair value range ₹12.0–₹25.56. Browse ASPIRA complete financial statements for revenue, profit, balance sheet and cash flow data.
Fair Value Analysis Export
ASPIRA Fair Value vs Current Price — Valuation Summary
ASPIRA average fair value, fair value range, price gap and valuation status across 5 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number. Read ASPIRA dividend yield for the complete payout history and dividend yield track record.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
ASPIRA Fair Value Analysis — Data Sources & Coverage
Aspira Pathlab financial data sources, valuation methods applied and sector benchmarks used — 2025 financial year. For live price and a broader fundamental view, visit ASPIRA share price.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
Data Currency: Financial data is from the previous year (2025).
ASPIRA vs Healthcare Services Sector Peers — P/E, P/B & Market Cap
Aspira Pathlab P/E ratio, P/B ratio and market capitalisation vs Healthcare Services sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Apollo Hospitals | APOLLOHOSP | 57.92 | 13.27 | ₹128,608 |
| Dr. Agarwal's Health Care | AGARWALEYE | 86.82 | 7.91 | ₹15,914 |
| Broach Lifecare Hospital | BROACH | - | - | ₹9 |
| Gujarat Kidney and Super… | GKSL | 81.75 | 5.41 | ₹1,332 |
| Jupiter Life Line Hospit… | JLHL | 44.49 | 5.79 | ₹8,320 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.